Camp4 Therapeutics Corp
Camp4 Therapeutics Corp (CAMP): 5 pipeline candidates · ~28 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
27.7 months
D/E 2.41 · 12% dilution
Lead: Phase 1
5 candidates
N/A
N/A
A transparent, data-derived signal for Camp4 Therapeutics Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$217.6M
Cash
$100.8M
Quarterly Burn
$11.0M
Runway
27.7 mo
Revenue
$1.3M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| cmp-001 | Phase 1 |
| cmp-002 | Preclinical |
| CMP-CPS-001 | Phase 1 |
| CMP-SYNGAP-01 | Preclinical |
| GBA1 discovery program | — |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
43
Total value held
$147.6M
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 12,615,272 | $55.8M |
| fmr llc | 4,933,432 | $21.8M |
| vanguard capital management llc | 3,069,536 | $13.5M |
| balyasny asset management l.p. | 2,632,437 | $11.6M |
| enavate sciences gp, llc | 2,190,920 | $9.7M |
| adage capital partners gp, l.l.c. | 1,960,784 | $8.6M |
| stonepine capital management, llc | 1,389,622 | $6.1M |
| harbourvest partners llc | 1,271,948 | $5.6M |
| silverarc capital management, llc | 653,594 | $2.9M |
| blackrock, inc. | 456,371 | $2.0M |
Showing top 10 of 43 institutional holders of Camp4 Therapeutics Corp. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Camp4 Therapeutics Corp's pipeline?
Camp4 Therapeutics Corp (CAMP) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Camp4 Therapeutics Corp's lead drug candidate?
Camp4 Therapeutics Corp's most advanced tracked candidate is cmp-001 (Phase 1) for Urea cycle disorders (UCDs).
What is Camp4 Therapeutics Corp's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Camp4 Therapeutics Corp has approximately 27.7 months of cash runway.
What is Camp4 Therapeutics Corp's market capitalization?
Camp4 Therapeutics Corp's market capitalization is approximately $217.6M.
Who is the CEO of Camp4 Therapeutics Corp?
Mr. Joshua Mandel-Brehm is the chief executive officer of Camp4 Therapeutics Corp (CAMP).
Get the full picture on Camp4 Therapeutics Corp
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.